{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:30:28Z","timestamp":1792985428001,"version":"4.5.0"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Proton-pump inhibitors (PPIs) have been associated with the risk of colonization with drug-resistant bacteria; however, possible confounding by lifestyle-associated factors and disease severity casts doubt on this association, and whether the risk is dose dependent is not known.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To assess the association between PPI use and the risk of acquiring drug-resistant Enterobacterales and to examine interactions with possible microbiome-altering agents.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This nested case-control study involved 2239 hospitalized adult (aged \u226518 years) patients identified from the microbiology laboratory database of Amsterdam University Medical Centers between December 31, 2018, and January 6, 2021. Patients in the case group had newly detected extended-spectrum \u03b2-lactamase (ESBL)\u2013 or carbapenemase-producing Enterobacterales (identified by clinical specimens). Risk-set sampling was used to assign patients with negative results for ESBL- and carbapenemase-producing Enterobacterales to the control group, who were then matched on a 5:1 ratio with patients in the case group by age and culture date. A second validation case-control study included matched pairs (1:1 ratio; 94 in each group) of patients who were prospectively enrolled.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Proton pump inhibitor use and clinical data at 30 days (primary exposure) and 90 days (secondary exposure) before the date of culture.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Adjusted incidence rate ratios (aIRRs) of ESBL- or carbapenemase-producing Enterobacterales acquisition by PPI dose and time risk windows (30 days for the primary outcome and 90 days for the secondary outcome) were estimated using conditional logistic regression models.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 2239 hospitalized patients (51.1% male; mean [SD] age, 60.9 [16.7] years), 374 were in the case group (51.6% male; mean [SD] age, 61.1 [16.5] years) and 1865 were in the matched control group (51.0% male; mean [SD] age, 60.9 [16.7] years). The aIRR for PPI use overall was 1.48 (95% CI, 1.15-1.91) at 30 days. Sensitivity analyses and the analysis of the pair-matched study with prospectively enrolled patients (aIRR, 2.96, 95% CI, 1.14-7.74) yielded similar results; findings were consistent in subgroups and corroborated by a negative-control exposure analysis. No association with microbiome-disturbing agents was found; laxatives and antibiotics were independently associated with a more than 2-fold increase in the risk of acquisition (antibiotics: aIRR, 2.78 [95% CI, 2.14-3.59]; laxatives: aIRR, 2.26 [95% CI. 1.73-2.94]).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this study, after careful control for confounding and sensitivity analyses, PPI use was associated with increases in the risk of acquiring ESBL- or carbapenemase-producing Enterobacterales among adult hospitalized patients. These findings emphasize the need for judicious use of PPIs.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.0470","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T11:01:41Z","timestamp":1677150101000},"page":"e230470","source":"Crossref","is-referenced-by-count":23,"title":["Association of Proton Pump Inhibitor Use With Risk of Acquiring Drug-Resistant Enterobacterales"],"prefix":"10.1001","volume":"6","author":[{"given":"Roel P. J.","family":"Willems","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology and Infection Prevention, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, Academic Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn C.","family":"Schut","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics, Amsterdam Public Health, Amsterdam University Medical Centers, Academic Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, Vrije University Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"Groot","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, Vrije University Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameen","family":"Abu-Hanna","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics, Amsterdam Public Health, Amsterdam University Medical Centers, Academic Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos W. R.","family":"Twisk","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Data Science, Amsterdam Public Health, Amsterdam University Medical Centers, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"van Dijk","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infection Prevention, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, Academic Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M. J. E.","family":"Vandenbroucke-Grauls","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infection Prevention, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, Academic Medical Center, Amsterdam, the Netherlands"},{"name":"Department of Clinical Medicine and Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"issue":"10325","key":"zoi230030r1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"issue":"14","key":"zoi230030r3","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa1914433","article-title":"Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012-2017.","volume":"382","author":"Jernigan","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi230030r4","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1111\/jgs.v67.12","article-title":"Low-value proton pump inhibitor prescriptions among older adults at a large academic health system.","volume":"67","author":"Mafi","year":"2019","journal-title":"J Am Geriatr Soc"},{"issue":"8","key":"zoi230030r5","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/MEG.0000000000000634","article-title":"Noncompliance with guidelines on proton pump inhibitor prescription as gastroprotection in hospitalized surgical patients who are prescribed NSAIDs.","volume":"28","author":"van den Bemt","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"zoi230030r6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jamainternmed.2020.0009","article-title":"Evaluation of the association between gastric acid suppression and risk of intestinal colonization with multidrug-resistant microorganisms: a systematic review and meta-analysis.","volume":"180","author":"Willems","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"5","key":"zoi230030r7","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/ajg.2007.102.issue-5","article-title":"The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use.","volume":"102","author":"Targownik","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"zoi230030r8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/jac\/dkab345","article-title":"Gastric acid suppression, lifestyle factors and intestinal carriage of ESBL and carbapenemase-producing Enterobacterales: a nationwide population-based study.","volume":"77","author":"Willems","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"zoi230030r9","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","article-title":"Proton pump inhibitors affect the gut microbiome.","volume":"65","author":"Imhann","year":"2016","journal-title":"Gut"},{"issue":"5","key":"zoi230030r10","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/apt.15604","article-title":"Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract-evidence from next-generation sequencing studies.","volume":"51","author":"Macke","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"7907","key":"zoi230030r11","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41586-022-04567-7","article-title":"Environmental factors shaping the gut microbiome in a Dutch population.","volume":"604","author":"Gacesa","year":"2022","journal-title":"Nature"},{"issue":"1","key":"zoi230030r12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41396-022-01321-9","article-title":"Gastric acid and escape to systemic circulation represent major bottlenecks to host infection by Citrobacter rodentium.","volume":"17","author":"Woodward","year":"2023","journal-title":"ISME J"},{"key":"zoi230030r13","first-page":"S10","article-title":"Proton pump inhibitor use and enteric infections.","volume":"104","author":"Dial","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"9596","key":"zoi230030r14","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"zoi230030r15","doi-asserted-by":"publisher","first-page":"k3532","DOI":"10.1136\/bmj.k3532","article-title":"The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE).","volume":"363","author":"Langan","year":"2018","journal-title":"BMJ"},{"issue":"1","key":"zoi230030r16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/00001648-200101000-00017","article-title":"Degree of matching and gain in power and efficiency in case-control studies.","volume":"12","author":"St\u00fcrmer","year":"2001","journal-title":"Epidemiology"},{"issue":"3","key":"zoi230030r18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1017\/S0195941700006603","article-title":"The role of colonization in the pathogenesis of nosocomial infections.","volume":"17","author":"Bonten","year":"1996","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"2","key":"zoi230030r19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/oxfordjournals.aje.a009786","article-title":"Factors influencing the optimal control-to-case ratio in matched case-control studies.","volume":"149","author":"Hennessy","year":"1999","journal-title":"Am J Epidemiol"},{"issue":"7","key":"zoi230030r20","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1086\/319600","article-title":"Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review.","volume":"32","author":"Harris","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"6","key":"zoi230030r22","first-page":"1887","article-title":"Robust causal inference using directed acyclic graphs: the R package \u2018dagitty\u2019.","volume":"45","author":"Textor","year":"2016","journal-title":"Int J Epidemiol"},{"key":"zoi230030r23","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1001\/jama.1963.03060120024016","article-title":"Studies of illness in the aged: the Index of ADL: a standardized measure of biological and psychosocial function.","volume":"185","author":"Katz","year":"1963","journal-title":"JAMA"},{"issue":"5","key":"zoi230030r24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"1","key":"zoi230030r25","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41467-019-14177-z","article-title":"Impact of commonly used drugs on the composition and metabolic function of the gut microbiota.","volume":"11","author":"Vich Vila","year":"2020","journal-title":"Nat Commun"},{"key":"zoi230030r26","doi-asserted-by":"publisher","first-page":"i969","DOI":"10.1136\/bmj.i969","article-title":"Analysis of matched case-control studies.","volume":"352","author":"Pearce","year":"2016","journal-title":"BMJ"},{"issue":"2","key":"zoi230030r27","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1093\/aje\/kwaa167","article-title":"Do case-control studies always estimate odds ratios?","volume":"190","author":"Labrecque","year":"2021","journal-title":"Am J Epidemiol"},{"issue":"3","key":"zoi230030r28","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10654-019-00494-6","article-title":"Principles of confounder selection.","volume":"34","author":"VanderWeele","year":"2019","journal-title":"Eur J Epidemiol"},{"issue":"12","key":"zoi230030r29","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.cmi.2017.03.026","article-title":"Risk factors for extended-spectrum \u00df-lactamase\u2013producing Escherichia coli urinary tract infection in the community in Denmark: a case-control study.","volume":"23","author":"S\u00f8gaard","year":"2017","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"zoi230030r30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cmi.2019.05.013","article-title":"Estimating the association between antibiotic exposure and colonization with extended-spectrum \u00df-lactamase\u2013producing gram-negative bacteria using machine learning methods: a multicentre, prospective cohort study.","volume":"26","author":"Tacconelli","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"zoi230030r31","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies.","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"},{"issue":"1","key":"zoi230030r32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s10654-006-9078-x","article-title":"Patterns of bias due to differential misclassification by case-control status in a case-control study.","volume":"22","author":"Chyou","year":"2007","journal-title":"Eur J Epidemiol"},{"issue":"6","key":"zoi230030r33","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1093\/ije\/dyu149","article-title":"Good practices for quantitative bias analysis.","volume":"43","author":"Lash","year":"2014","journal-title":"Int J Epidemiol"},{"issue":"4","key":"zoi230030r34","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.v30.4","article-title":"Multiple imputation using chained equations: issues and guidance for practice.","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"issue":"9","key":"zoi230030r35","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1093\/aje\/kwab056","article-title":"Matched versus unmatched analysis of matched case-control studies.","volume":"190","author":"Wan","year":"2021","journal-title":"Am J Epidemiol"},{"issue":"1","key":"zoi230030r36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/jac\/dkab373","article-title":"The impact of non-antimicrobial drug agents on the acquisition of ESBL-producing Enterobacterales in non-critical care wards in a German university hospital: an exploratory, matched case-control study.","volume":"77","author":"Klauke","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"zoi230030r37","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.07.038"},{"key":"zoi230030r38","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-136-11-200206040-00013"},{"issue":"9","key":"zoi230030r39","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/cid\/ciy358","article-title":"Acquisition of multidrug-resistant organisms in the absence of antimicrobials.","volume":"67","author":"D\u2019Agata","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"2","key":"zoi230030r40","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S1473-3099(01)00066-4","article-title":"Effect of antimicrobial agents on the ecological balance of human microflora.","volume":"1","author":"Sullivan","year":"2001","journal-title":"Lancet Infect Dis"},{"issue":"20","key":"zoi230030r41","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1001\/jama.2008.723","article-title":"Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects.","volume":"300","author":"Vandenbroucke","year":"2008","journal-title":"JAMA"},{"issue":"3","key":"zoi230030r42","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1053\/j.gastro.2019.05.056","article-title":"Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin.","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"key":"zoi230030r2","unstructured":"Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019. US Dept of Health and Human Services; December 2019. Accessed April 15, 2022. https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf"},{"key":"zoi230030r17","unstructured":"European Committee on Antimicrobial Susceptibility Testing. EUCAST Guidelines for Detection of Resistance Mechanisms and Specific Resistances of Clinical and\/or Epidemiological Importance. Version 2.0. European Society of Clinical Microbiology and Infectious Diseases. July 2017. Accessed June 4, 2018. https:\/\/aurosan.de\/images\/mediathek\/servicematerial\/EUCAST_detection_of_resistance_mechanisms.pdf"},{"key":"zoi230030r21","unstructured":"World Health Organization Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. WHO Collaborating Centre for Drug Statistics Methodology; 2018. Accessed January 5, 2019. https:\/\/www.drugsandalcohol.ie\/29364\/1\/WHO%20Collaborating%20Centre%20for%20Drug%20Statistics%20Methodology.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2801744\/willems_2023_oi_230030_1676399890.52856.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T11:01:47Z","timestamp":1677150107000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2801744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.0470","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,23]]}}}